BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs.
BioNTech收購了中國抗癌藥製造商普米斯生物技術(Biotheus)，交易價值接近10億美元。這家新冠疫苗研發商擬利用中國在健康科學領域的專長開發有前景的免疫治療藥物。
The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda, the best-selling drug globally in 2023 with $25bn in sales.
這筆交易讓這家德國生物技術公司控制一類藥物，該類藥物已顯示出超越默沙東(MSD)重磅抗癌藥可瑞達(Keytruda)的潛力，後者是2023年全球最暢銷藥物，銷售額達250億美元。
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn.
BioNTech將向總部位於廣東省的製藥商普米斯支付8億美元預付款，之後支付最高1.5億美元的里程碑付款。